Variant report
Variant | nsv961792 |
---|---|
Chromosome Location | chr2:72515945-72518734 |
allele | n/a |
Outlinks | Ensembl   UCSC |
- TF binding region (count:0)
- CpG islands (count:0)
- Chromatin interactive region (count:0)
- LncRNA region (count:1)
- Mature miRNA region (count: 0)
- miRNA target sites (count:0)
No data |
No data |
No data |
(count:1 , 50 per page) page:
1
No. | lncRNA name | Chromosome Location | lncRNA alias |
---|---|---|---|
1 | lnc-SPR-3 | chr2:72515914-72516239 | NONHSAT071576 |
No data |
No data |
No data |
No. | Variant name | Chromosome position | Chromatin state | Related regulatory elements | Target genes | Extended variants | Associated traits |
---|---|---|---|---|---|---|---|
1 | rs182382406 | chr2:72516004-72516005 | Inactive region | lncRNA | n/a | Overlapped CNVs | n/a |
2 | rs75089953 | chr2:72516125-72516126 | Inactive region | lncRNA | n/a | Overlapped CNVs | n/a |
3 | rs563421845 | chr2:72516141-72516142 | Inactive region | lncRNA | n/a | Overlapped CNVs | n/a |
4 | rs530877307 | chr2:72516142-72516143 | Inactive region | lncRNA | n/a | Overlapped CNVs | n/a |
5 | rs571285676 | chr2:72516182-72516183 | Inactive region | lncRNA | n/a | Overlapped CNVs | n/a |
6 | rs187844483 | chr2:72516184-72516185 | Inactive region | lncRNA | n/a | Overlapped CNVs | n/a |
7 | rs145829874 | chr2:72516243-72516244 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
8 | rs527718578 | chr2:72516253-72516254 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
9 | rs371902080 | chr2:72516275-72516276 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
10 | rs62149274 | chr2:72516283-72516284 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
11 | rs376364816 | chr2:72516285-72516286 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
12 | rs547262290 | chr2:72516302-72516303 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
13 | rs147825675 | chr2:72516334-72516335 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
14 | rs719117 | chr2:72516353-72516354 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | mRNA abundance |
15 | rs141332071 | chr2:72516358-72516359 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
16 | rs569784346 | chr2:72516385-72516386 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
17 | rs537103722 | chr2:72516395-72516396 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
18 | rs719120 | chr2:72516421-72516422 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
19 | rs371724655 | chr2:72516434-72516435 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
20 | rs576772834 | chr2:72516439-72516440 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
21 | rs535801100 | chr2:72516440-72516441 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
22 | rs719119 | chr2:72516574-72516575 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
23 | rs193222237 | chr2:72516575-72516576 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
24 | rs369044925 | chr2:72516617-72516618 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
25 | rs143625641 | chr2:72516669-72516670 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
26 | rs386647288 | chr2:72516701-72516702 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
27 | rs719118 | chr2:72516703-72516704 | Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
28 | rs567810013 | chr2:72516720-72516721 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
29 | rs190063479 | chr2:72516721-72516722 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
30 | rs545887264 | chr2:72516784-72516785 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
31 | rs192924709 | chr2:72516811-72516812 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
32 | rs564180221 | chr2:72516845-72516846 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
33 | rs528470550 | chr2:72516861-72516862 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
34 | rs183957539 | chr2:72516904-72516905 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
35 | rs562425895 | chr2:72516907-72516908 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
36 | rs371710705 | chr2:72516916-72516917 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
37 | rs544512838 | chr2:72516949-72516950 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
38 | rs115089140 | chr2:72516957-72516958 | Enhancers | n/a | n/a | Overlapped CNVs | n/a |
39 | rs148056550 | chr2:72517055-72517056 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
40 | rs569427430 | chr2:72517058-72517059 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
41 | rs537189917 | chr2:72517079-72517080 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
42 | rs552294957 | chr2:72517093-72517094 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
43 | rs570390687 | chr2:72517105-72517106 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
44 | rs531931795 | chr2:72517163-72517164 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
45 | rs141430535 | chr2:72517225-72517226 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
46 | rs10207299 | chr2:72517296-72517297 | Weak transcription Enhancers | n/a | n/a | LD-proxies of rSNPOverlapped rCNV | n/a |
47 | rs370066470 | chr2:72517380-72517381 | Weak transcription Enhancers | n/a | n/a | Overlapped CNVs | n/a |
48 | rs150408543 | chr2:72517423-72517424 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
49 | rs188730734 | chr2:72517434-72517435 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
50 | rs550425289 | chr2:72517497-72517498 | Weak transcription | n/a | n/a | Overlapped CNVs | n/a |
Disease | PMID | Source |
---|---|---|
Chronic lymphocytic leukemia | 21546498 | CNVD |
Diffuse large b-cell lymphoma | 18287131 | CNVD |
Ovarian neoplasms | 16753589 | CNVD |
Glioblastoma multiforme | 17387387 | CNVD |
Neuroblastoma | 17533364 | CNVD |
Neuroblastoma | 18923191 | CNVD |
Endometrial cancer | 22040021 | CNVD |
Adrenal tumor | 17535989 | CNVD |
Breast cancer | 21264507 | CNVD |
Basal cell lymphoma | 17053054 | CNVD |
Medulloblastoma | 17522785 | CNVD |
Cancer | 23418310 | CNVD |
Medulloblastoma | 21979893 | CNVD |
Breast cancer | 17603634 | CNVD |
Ewing''s sarcoma | 21437220 | CNVD |
Glioblastoma multiforme | 21080181 | CNVD |
Ependymoma | 16718352 | CNVD |
Prostate cancer | 18632612 | CNVD |
Thoracic aortic aneurysm | 21092924 | CNVD |
Intellectual disability | 22102821 | CNVD |
Cancer | 20164919 | CNVD |
Hodgkin''s lymphoma | 18641027 | CNVD |
Follicular lymphoma | 20505157 | CNVD |
Autism | 17483303 | CNVD |
Myofibroblastic sarcoma | 19369631 | CNVD |
Hodgkin''s lymphoma | 17606441 | CNVD |
Esophageal adenocarcinoma | 18519675 | CNVD |
Medulloblastoma | 20607354 | CNVD |
Autism | 22495311 | CNVD |
Autism | 18522746 | CNVD |
Lung cancer | 18438408 | CNVD |
Neurodevelopmental disorder | 22521361 | CNVD |
Melanoma | 18172304 | CNVD |
Cancer | 16751803 | CNVD |
T-cell prolymphocytic leukemia | 19278963 | CNVD |
Acute lymphoblastic leukemia | 20067559 | CNVD |
Acute lymphoblastic leukemia | 21980252 | CNVD |
Developmental delay | 21147756 | CNVD |
Carcinoma ex pleomorphic adenoma | 18828159 | CNVD |
Non-syndromic sensorineural hearing loss | 15273396 | CNVD |
Seminomas | 18059402 | CNVD |
Testicular germ cell tumor | 18059402 | CNVD |
Invasive pancreatic ductal carcinoma | 16982739 | CNVD |
Myeloproliferative neoplasm | 20015882 | CNVD |
Hepatocellular carcinoma | 16750200 | CNVD |
Renal cell carcinoma | 18765545 | CNVD |
Myxofibrosarcoma | 16751306 | CNVD |
Myelofibrosis | 22110671 | CNVD |
small cell lung cancer | 20016488 | CNVD |
Breast cancer | 22522925 | CNVD |
Acute myeloid leukemia | 21251322 | CNVD |
Pancreatic cancer | 17952125 | CNVD |
Non-syndromic sensorineural hearing loss | 18451855 | CNVD |
No. | Chromosome Location | Chromatin state | Cell line | Tissue |
---|---|---|---|---|
1 | chr2:72516200-72517400 | Enhancers | NHDF-Ad | bronchial |
2 | chr2:72516800-72517000 | Enhancers | Adipose Derived Mesenchymal Stem Cell Cultured Cells | ES cell derived |
3 | chr2:72516800-72517000 | Enhancers | Muscle Satellite Cultured Cells | -- |
4 | chr2:72516800-72517000 | Enhancers | Osteobl | bone |
5 | chr2:72516800-72517400 | Enhancers | Breast variant Human Mammary Epithelial Cells (vHMEC) | Breast |
6 | chr2:72517000-72518200 | Weak transcription | Osteobl | bone |
7 | chr2:72517000-72518600 | Weak transcription | Adipose Derived Mesenchymal Stem Cell Cultured Cells | ES cell derived |
8 | chr2:72517000-72520600 | Weak transcription | Muscle Satellite Cultured Cells | -- |
9 | chr2:72517400-72521000 | Weak transcription | NHDF-Ad | bronchial |
10 | chr2:72517800-72520600 | Enhancers | A549 | lung |
11 | chr2:72518200-72518600 | Enhancers | Osteobl | bone |
12 | chr2:72518200-72518800 | Enhancers | hESC Derived CD56+ Mesoderm Cultured Cells | ES cell derived |
13 | chr2:72518200-72518800 | Enhancers | Mesenchymal Stem Cell Derived Chondrocyte Cultured Cells | embryonic stem cell |
14 | chr2:72518200-72518800 | Enhancers | Fetal Adrenal Gland | Adrenal Gland |
15 | chr2:72518200-72519000 | Enhancers | Mesenchymal Stem Cell Derived Adipocyte Cultured Cells | ES cell derived |
16 | chr2:72518400-72518800 | Enhancers | Fetal Lung | lung |
17 | chr2:72518600-72518800 | Enhancers | Bone Marrow Derived Cultured Mesenchymal Stem Cells | Bone marrow |
18 | chr2:72518600-72519200 | Enhancers | Adipose Derived Mesenchymal Stem Cell Cultured Cells | ES cell derived |
19 | chr2:72518600-72520600 | Weak transcription | Osteobl | bone |